Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Non-Current Deffered Revenue (2016 - 2024)

Rhythm Pharmaceuticals (RYTM) has disclosed Non-Current Deffered Revenue for 8 consecutive years, with $109.2 million as the latest value for Q3 2024.

  • Quarterly Non-Current Deffered Revenue rose 4.34% to $109.2 million in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $109.2 million through Sep 2024, up 4.34% year-over-year, with the annual reading at $106.1 million for FY2023, 40.01% up from the prior year.
  • Non-Current Deffered Revenue for Q3 2024 was $109.2 million at Rhythm Pharmaceuticals, up from $108.4 million in the prior quarter.
  • The five-year high for Non-Current Deffered Revenue was $109.2 million in Q3 2024, with the low at $3.0 million in Q1 2020.
  • Average Non-Current Deffered Revenue over 4 years is $85.7 million, with a median of $104.7 million recorded in 2023.
  • The sharpest move saw Non-Current Deffered Revenue soared 40.01% in 2023, then grew 4.34% in 2024.
  • Over 4 years, Non-Current Deffered Revenue stood at $3.0 million in 2020, then surged by 2462.01% to $75.8 million in 2022, then skyrocketed by 40.01% to $106.1 million in 2023, then rose by 2.92% to $109.2 million in 2024.
  • According to Business Quant data, Non-Current Deffered Revenue over the past three periods came in at $109.2 million, $108.4 million, and $107.4 million for Q3 2024, Q2 2024, and Q1 2024 respectively.